Articles tagged with Vaccine Development
The National Institute of Allergy and Infectious Diseases has launched four public-private partnerships to accelerate the development of promising HIV/AIDS vaccines. The partnerships aim to tap into the skills of both private industry and academic research centers, with a focus on developing vaccines for use around the world.
Maternal mortality remains a global health problem, despite significant international efforts. A new $4.95 million grant will aid in developing tools to diagnose and treat ectopic pregnancy, prevent preeclampsia, and identify women at risk of life-threatening infections.
The companies identified a family of proteins called Potassium Channel Interacting Proteins (KChIPs) that regulate A-type potassium channels, which control brain electrical signals. These KChIPs may lead to the development of new therapeutics for CNS disorders with minimal side effects.
Researchers have developed a new method to explore autoimmune mechanisms in chronic Lyme disease, which could lead to better diagnosis and treatment. The technique identifies specific bits of the Lyme agent that trigger an immune response against the body's own cells.
Researchers created a transgenic rat model with human CETP to study atherosclerosis. The study showed that elevated CETP contributes to the development of atherosclerosis, supporting the use of an antibody-based vaccine to raise HDL cholesterol levels.
The AVANT rotavirus vaccine demonstrated nearly 90% efficacy in preventing rotavirus disease in infants, surpassing existing vaccines' 49-68% efficacy rates. The vaccine was also found to be safe and immunogenic, with minimal side effects reported.
Researchers at The Wistar Institute are developing vaccines targeting the mucosal immune system to prevent HIV-1 and human papilloma virus infections. They aim to induce neutralizing antibodies and killer T cells to prevent cancerous transformations in cells, with a focus on cervical cancer caused by HPV.
The Wistar Institute's Regeneration Symposium will feature talks on epimorphic regeneration, limb regeneration, and the role of ependymal cells in spinal cord regeneration. Experts like David Stocum, Alejandro Sanchez Alvarado, and Susan V. Bryant will share their research findings.
The Wistar Institute hosted a symposium on regenerative biology, featuring experts discussing recent advances in understanding regeneration in metazoans, stem cells, and nervous systems. Key findings included insights into limb regeneration, spinal cord repair, and muscle cell replacement.
Dr. Keith Wailoo, a UNC associate professor, has been awarded a $1 million James S. McDonnell Centennial Fellowship to study disease and biomedicine in the 20th century. He will investigate how people's ideas about illnesses like breast cancer and sickle cell anemia have changed over time.
BioStratum's gene-attenuated virus vaccines protect macaque monkeys against HIV-1-based viruses. The study demonstrates the efficacy of two vaccines in preventing AIDS development in 11 out of 12 monkeys.
Researchers at The Wistar Institute have discovered two genes, Alphav and Beta3, that play a crucial role in melanoma development. These findings suggest that blocking the activity of the vitronectin receptor could be an effective way to prevent cancer progression.
Scientists have developed a new TB vaccine candidate that uses recombinant BCG strains to secrete pore-forming listeriolysin, improving its ability to stimulate CD8 T cells. This could lead to better protection against M. tuberculosis infection and potentially halve the estimated 2050 global TB cases.
A human clinical trial of an edible vaccine has shown promising results, indicating that consumption can result in immunity to specific diseases. The vaccine was tested on volunteers who ate genetically altered potatoes and showed a significant immune response, with antibodies found in both blood and stool samples.
Dr. Richard Facklam, CDC Lab Chief, receives award for his contributions to clinical microbiology research, focusing on streptococci identification and pneumococcal vaccine development. He has also worked on antimicrobial resistance studies in developing countries.
The company has validated the VEGF receptor as a key target in pathological angiogenesis and expects to submit an Investigational New Drug (IND) Application for clinical trials in cancer by the end of 1998. RPI.4610 has shown activity in multiple animal models, including inhibition of tumor growth and metastasis.